Molecular Genetic and Pathological Studies of Anal Tumors
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Study the Genetics of Anal Cancer
| Condition | Intervention |
|---|---|
|
Rectal Cancer Colon Cancer Colonic Neoplasms Anal Cancer |
Other: genetic analysis |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Molecular Genetic and Pathological Studies of Anal Tumors |
- Genetic analysis of blood sample as well as tissues , will provide us with any possible tumor marker for a better prognostic indicator. [ Time Frame: Annual assessment. ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
whole blood
| Estimated Enrollment: | 300 |
| Study Start Date: | September 2004 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
-
Other: genetic analysis
To determine the status of previously identified anal cancer molecular markers and any correlations with outcome as well as to discover new molecular biomarkers through correlating molecular data with clinical outcome. Study of tissue samples and cells from biopsies of your lesion and blood sample. We hope to learn the role genes and proteins may play in the development of anal cancer. Experiments will be performed using this tissue and blood, include analysis of DNA, analysis of RNA expression levels, analysis of protein levels of important gene products, and development of tissue culture cell lines.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Adult patients with anal cancer or high risk for anal cancer refered to Stanford.
Inclusion Criteria:Inclusion Criteria:
- Patients with anal tumors
- Undergoing surgery for elective colon and rectal surgery
Exclusion Criteria:No other patients other than adult patients with anal cancer or high risk for anal cancer refered to Stanford will be enrolled to the study. No Children will be included to the study
Contacts and Locations| Contact: Moe Jalali | (650) 724-4023 | moej@stanford.edu |
| United States, California | |
| Stanford University School of Medicine | Recruiting |
| Stanford, California, United States, 94305 | |
| Contact: Moe Jalali 650-724-4023 moej@stanford.edu | |
| Contact: Cancer Clinical Trials Office (650) 498-7061 | |
| Principal Investigator: Mark Lane Welton | |
| Sub-Investigator: Nader Pourmand | |
| Sub-Investigator: Dr Andrew Shelton | |
| Sub-Investigator: George Albert Fisher M.D. Ph.D. | |
| Sub-Investigator: James M Ford | |
| Sub-Investigator: Hanlee P. Ji | |
| Principal Investigator: | Mark Lane Welton | Stanford University |
More Information
No publications provided
| Responsible Party: | Stanford University |
| ClinicalTrials.gov Identifier: | NCT00267787 History of Changes |
| Other Study ID Numbers: | ANAL0001, 95340, ANAL0001 |
| Study First Received: | December 19, 2005 |
| Last Updated: | July 5, 2012 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Anus Neoplasms Neoplasms Colonic Neoplasms Rectal Neoplasms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms |
Neoplasms by Site Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases Anus Diseases Rectal Diseases Colonic Diseases |
ClinicalTrials.gov processed this record on June 17, 2013